Prostate Stem Cell Antigen Expression in Radical Prostatectomy Specimens Predicts Early Biochemical Recurrence in Patients with High Risk Prostate Cancer Receiving Neoadjuvant Hormonal Therapy.

We aimed to identify tissue biomarkers that predict early biochemical recurrence (BCR) in patients with high-risk prostate cancer (PC), toward the goal of increasing the benefits of neoadjuvant hormonal therapy (NHT).

In 2005-2012, prostatectomy specimens were collected from 134 PC patients who had received NHT and radical prostatectomy. The expression of 13 tissue biomarkers was assessed in the specimens via immunohistochemistry. Time to BCR and factors predictive of BCR were determined by using the Cox proportional hazards model. During the follow-up period (median, 57.5 months), 67 (50.0%) patients experienced BCR. Four (3.0%) patients were tumor-free in the final pathology assessment, and 101 (75.4%) had negative resection margins. Prostate stem cell antigen (PSCA) was the only significant prognostic tissue biomarker of BCR [hazard ratio (HR), 2.58; 95% confidence interval (CI), 1.06-6.27; p = 0.037] in a multivariable analysis adjusted by the clinicopathological variables that also significantly predicted BCR; these were seminal vesicle invasion (HR, 2.39; 95% CI, 1.32-4.34), initial prostate serum antigen level (HR 1.01; 95% CI, 1.001-1.020), prostate size (HR, 0.93; 95% CI, 0.90-0.97), and the Gleason score of preoperative biopsies (HR, 1.34; 95% CI, 1.01-1.79). We suggest that PSCA is a useful tissue marker for predicting BCR in patients with high risk PC receiving NHT and radical prostatectomy.

PloS one. 2016 Mar 16*** epublish ***

Sung Han Kim, Weon Seo Park, Sun Ho Kim, Boram Park, Jungnam Joo, Geon Kook Lee, Jae Young Joung, Ho Kyung Seo, Jinsoo Chung, Kang Hyun Lee

Department of Urology, Center for Prostate Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea., Department of Urology, Center for Prostate Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea., Department of Radiology, Center for Prostate Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea., Biometric Research Branch, Research Institute and Hospital, National Cancer Center, Goyang, Korea., Biometric Research Branch, Research Institute and Hospital, National Cancer Center, Goyang, Korea., Department of Pathology, Center for Prostate Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea., Department of Urology, Center for Prostate Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea., Department of Urology, Center for Prostate Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea., Department of Urology, Center for Prostate Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea., Department of Urology, Center for Prostate Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe